Experience with antiviral therapy in patients with chronic hepatitis C and metabolic syndrome

Relevance. This article presents the results of clinical studies on the use of antiviral drugs for treating chronic hepatitis C (CHC) and metabolic syndrome (MS).

Objective. Analysis of the effectiveness of CHC therapy and its impact on the components of MS.

Materials and methods. The study was conducted at the Yaroslavl Regional Infectious Diseases Clinical Hospital between 2015 and 2023. All patients were prescribed a standard set of clinical, laboratory, and instrumental examinations upon admission to the hospital (general and biochemical blood tests, blood tests for HCV genotype and viral load, ultrasound of the abdominal organs). Treatment was performed using different antiviral regimens.

Results. Among the regimens used, only interferon-containing regimens resulted in changes in the components of metabolic syndrome. A significant decrease in abdominal obesity and triglyceride levels was observed (p< 0.05) The changes mainly affected patients with genotypes 2 and 3, which confirms the "viral" genesis of the development of these components of MS.

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958- 65. doi: 10.1016/s0140-6736(01)06102-5.

2. Бурневич Э.З., Никулкина Е.Н., Щаницына С.Е. Комбинация даклатасвира и асунапревира в лечении хронического гепатита С у больных, инфицированных HCV 1 генотипа. Клиническая фармакология и терапия. 2015;24(4):21-26. [Burnevich EZ, Nikulkina EN, Shchanitsyna SE. Combination of daclatasvir and asunaprevir in the treatment of chronic hepatitis C in patients infected with HCV genotype 1. Clinical pharmacology and therapy. 2015;24(4):21-26. (In Rus.)].

3. Бацких С.Н. Безинтерфероновая терапия хронического гепатита С: смена препаратов или новая парадигма лечения? Российский журнал гастроэнтерологии, колопроктологии. 2014;24(4):23-31. [Batskikh SN. Interferon-free therapy for chronic hepatitis C: a change of drugs or a new treatment paradigm? Russian Journal of Gastroenterology, Coloproctology. 2014;24(4):23-31. (In Rus.)].

4. Taremi SS, Beyer B, Maher M, et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Science : a Publication of the Protein Society. 1998 Oct;7(10):2143-2149. DOI: 10.1002/pro.5560071011.

5. Сагалова О.И. Безинтерфероновый режим паритапревир/ритонавир-омбитасвир-дасабувир в лечении больных хроническим гепатитом С, обусловленным вирусом генотипа 1 (обзор результатов клинических исследований). Клинические перспективы гастроэнтерологии, гепатологии. 2015;2:2-11. [Sagalova OI. Interferon-free paritaprevir/ritonavir-ombitasvir-dasabuvir regimen in the treatment of patients with chronic hepatitis C caused by genotype 1 virus (review of clinical research results). Clinical perspectives of gastroenterology, hepatology. 2015;2:2-11. (In Rus.)].

6. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014 Feb;34(1):22-9. doi: 10.1055/s-0034-1371007.

7. Абурахманов Д.Т., Абдулаев С.М., Бурневич Э.З. Стеатоз печени и инсулинорезистентность при хроническом гепатите С. Гепатологический форум. 2007;3:21-25. [Aburakhmanov DT, Abdulaev SM, Burnevich EZ. Liver steatosis and insulin resistance in chronic hepatitis C. Hepatological Forum. 2007;3:21-25. (In Rus.)].

8. Малеев В.В., Ситников И.Г., Бохонов М.С. Вопросы гепатологии: учебное пособие / под ред. В.В. Малеева - Санкт-Петербург: СпецЛит, 2016. - 367 с. [Maleev V.V., Sitnikov I.G., Bokhonov M.S. Questions of hepatology: a textbook / edited by V.V. Maleev – St. Petersburg: SpetsLit, 2016. - 367 p.].